ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery

作者：Jennifer L. Sherr, Melissa J. Schoelwer, Tiago Jeronimo Dos Santos, Leenatha Reddy, Torben Biester, Alfonso Galderisi, J C van Dyk, Marisa E. Hilliard, Cari Berget, Linda Anne DiMeglio · 发表于：Pediatric Diabetes · 年份：2022 · DOI：10.1111/pedi.13421 · 被引用次数：151 · 研究领域：Diabetes Management and Research、Diabetes and associated disorders、Diabetes Treatment and Management

J.L.S. reports having received speaker honoraria from Eli Lilly, Insulet, Medtronic, and Zealand and serves on advisory boards of Bigfoot Biomedical, Cecelia Health, Insulet Corporation, Medtronic Diabetes, JDRF T1D Fund, and Vertex. She has been a consultant for Insulet and Medtronic. J.L.S.'s institution received research grant support from JDRF, Medtronic, Insulet, and NIDDK. M.S. reports research grant support, paid to her institution, from Tandem Diabetes Care, Insulet, Medtronic, JDRF, and NIDDK. T.S. has no conflict to disclose. L.R. reports speaker fees from Sanofi, Pfizer, NovoNordisk. T.B. reports speaker fees, consulting honoraria or research support from AstraZeneca, Ascensia, DexCom, Medtronic, NovoNordisk, Roche, Sanofi, and Ypsomed. Since 2021, he is member of the Expert group for medical devices of the European Medicines Agency. A.G. received speaker honoraria from Ypsomed. A.G.'s institution received research support from the European Commission (H2020 program). J.V. has no conflict to disclose. M.E.H. receives research grant support from NIDDK, JDRF, and The Leona M. and Harry B. Helmsley Charitable Trust. C.B. has been a consultant for Insulet. L.A.D. reports that in the last 3 years she has consulted for Vertex and served on a Mannkind, Merck, and Abata adivosry board. She has also recieved research support to her instiution from Caladrius, Lilly, Mannkind, Medtronic, Provention, and Zealand. The peer review history for this article is available at https:/...